阿帕替尼对不同血供晚期胃癌患者的临床疗效和安全性  

Clinical efficacy and safety of apatinib in advanced gastric cancer with different blood supply

作　　者：陈琦[1,2] 胡长路 魏欣 王丹[2] 刘家佳 朱奇志 徐维平[2,3] CHEN Qi;HU Chang-lu;WEI Xin;WANG Dan;LIU Jia-jia;ZHU Qi-zhi;XU Wei-ping(Department of Medical Oncology,The First Affiliated Hospital of USTC/Anhui Provincial Hospital,Hefei 230031,China;University of Science and Technology of China,Hefei 230026,China;Department of Geriatrics,The First Affiliated Hospital of USTC/Anhui Provincial Hospital/Gerontology Institute of Anhui Province,Hefei 230001,China)

机构地区：[1]中国科学技术大学附属第一医院/安徽省立医院肿瘤内科,合肥230031 [2]中国科学技术大学,合肥230026 [3]中国科学技术大学附属第一医院/安徽省立医院老年医学科/安徽省老年医学研究所,合肥230001

出　　处：《中国新药杂志》2023年第15期1546-1551,共6页Chinese Journal of New Drugs

摘　　要：目的:探讨阿帕替尼对不同血供晚期胃癌患者的临床疗效和安全性。方法:回顾性分析45例阿帕替尼治疗的不同血供晚期胃癌患者的临床资料,将同层面动脉期与平扫期CT值的差值≥40 HU纳入A组,≥20 HU且<40 HU纳入B组,<20 HU纳入C组,比较3组患者的治疗效果、血清癌胚抗原(CEA)、血清糖类抗原199(CA199)、生存情况、安全性之间的差异。结果:A组患者的客观缓解率、疾病控制率显著高于B组以及C组,差异存在统计学意义(P<0.05);经过治疗后,3组患者的CEA及CA199均显著下降,且通过两两比较,3组患者的CEA和CA199从高到低依次为C,B,A组,3组患者的无进展生存期(PFS)之间的差异存在统计学意义(P<0.05),经过两两比较,3组患者的PFS从高到低依次为A,B,C组;3组患者的不良事件(AE)之间的差异不存在统计学意义(P>0.05)。结论:阿帕替尼在富血供晚期胃癌中临床疗效优于乏血供晚期胃癌,在富血供晚期胃癌和乏血供晚期胃癌中治疗安全性相同。Objective:To investigate the clinical efficacy and safety of apatinib in advanced gastric cancer with different blood supply.Methods:The clinical data of 45 patients with advanced gastric cancer with different blood supply treated with apatinib were analyzed retrospectively.The patients with the difference of CT values between arterial phase and plain scan at the same level≥40 HU were included in group A,≥20 HU and<40 HU in group B,and<20 HU in group C.The therapeutic effects,serum carcinoembryonic antigen(CEA),carbohydrate antigen199(CA199),survival and safety of the three groups were compared.Results:The objective remission rate and disease control rate of group A were significantly higher than those of group B and group C(P<0.05).After treatment,the CEA and CA199 of the three groups decreased significantly,and through pairwise comparison,the CEA and CA199 of the three groups ranked C,B and A from high to low.There was significant difference in PFS among the three groups(P<0.05).After pairwise comparison,the PFS of the three groups ranked A,B and C from high to low.The difference of adverse events among the three groups was not statistically significant(P>0.05).Conclusion:The clinical efficacy of apatinib in rich blood supply advanced gastric cancer is better than that in lack of blood supply advanced gastric cancer.It has the same safety in rich blood supply advanced gastric cancer and lack of blood supply advanced gastric cancer.

关 键 词：阿帕替尼 不同血供 晚期胃癌 临床疗效 安全性 

分 类 号：R979.1[医药卫生—药品]